Limestone Investment Advisors
DMII icon

Limestone Investment Advisors’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Limestone Investment Advisors’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Buy
151,000
+139,100
+1,169% +$1.4M 0.11% 152
2026
Q1 		$119K Buy
+11,900
New +$119K 0.01% 335

Other funds holding DMII

Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Tenor Capital Management
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Limestone Investment Advisors's DMII Position: Q2 2026 in Review

Limestone Investment Advisors increased its Drugs Made In America Acquisition II Corp (DMII) stake by 1,169% in Q2 2026, buying an estimated $1.4M and bringing the position to 151,000 shares worth $1.52M. The position accounts for 0.11% of the portfolio, ranked #152.

Limestone Investment Advisors first reported a position in DMII in Q1 2026 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Limestone Investment Advisors held 151,000 shares of Drugs Made In America Acquisition II Corp worth $1.52M as of Q2 2026.
  • Limestone Investment Advisors bought 139,100 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $1.4M.
  • Drugs Made In America Acquisition II Corp made up 0.11% of Limestone Investment Advisors's portfolio in Q2 2026, its #152 holding.
  • Limestone Investment Advisors first reported a position in Drugs Made In America Acquisition II Corp in Q1 2026 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Limestone Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.